Replimune Shares Top 52-Week High After Submitting Application for Melanoma Treatment

By MarketWatch | Nov 21, 2024 at 04:49 PM EST

Replimune Group's stock surged to a 52-week high in after-hours trading after receiving breakthrough therapy designation for RP1 and submitting a biologics license application. The stock jumped 22% to $13.50, closing at $11.05 in the regular session.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.